ARS PHARMACEUTICALS INC. - COMMON STOCK

ARS Pharmaceuticals Reacquires European Marketing Rights to neffy® (ARS-1) for the Treatment of Type I Allergic Reactions Including Anaphylaxis

22 Feb 2023 16:05:01 By Nasdaq GlobeNewswire

ARS Pharmaceuticals to Participate in the SVB Securities Virtual Global Biopharma Conference 2023

09 Feb 2023 06:30:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis

10 Nov 2022 08:00:03 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Closes Merger with Silverback Therapeutics

08 Nov 2022 16:02:00 By Nasdaq GlobeNewswire